Hu, Chun-Mei

HuCM 6x7Assistant Professor


E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-2789-8777

 

EDUCATION AND POSITIONS HELD:

  • Ph.D., Institute of Biochemistry and Molecular Biology, National Taiwan University, College of Medicine, 2010
  • Postdoctoral Fellow, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, 2010-2012
  • Postdoctoral Fellow, Department of Biological Chemistry, School of Medicine, University of California, Irvine, USA, 2012-2013
  • Postdoctoral Fellow, Genomics Research Center, Academia Sinica, 2013-2014
  • Regular Postdoctoral Fellow, Academia Sinica, 2014
  • Assisant Research Specialist, Genomics Research Center, Academia Sinica, 2014-2019
  • Assisant Professor, Genomics Research Center, Academia Sinica, 2019-present

HONORS:

  • Award for Excellent Ph.D. Thesis from the Chien-Tien Hsu Cancer Research Foundation at the 7th Symposium on Recent Advances in Cellular and Molecular Biology, 1999
  • Excellence Award The first session of the Merck Award for young biotech, 2008
  • Excellence Award National Taiwan University Graduate Award for outstanding work, 2008

EXPERTISE:

  • Nucleotide metabolism and genomic instability studies
  • Tumorigenic activity assay (including the determination of growth rate, mutation rate, soft-agar colony formation and tumorigenecity in nude/scid mice).
  • Polyclonal antibody generation
  • Develop method for high-throughput drug screening
  • Identify small molecules for targeted therapy
  • Uncover drug action mechanism

PATENTS

  • Chang ZF, Fang JM, Hu CM, Yeh MT. Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells. US20130252953 A1, CN103476411A, WO2012072019A1. 2013
  • Lee WH, Zhu J, Qiu XL, Hu CM. Small Molecule Modifiers of The Hec1-Nek2 Interaction In G2/M. UC2013-847-1

SELECTED PUBLICATIONS:

  • Hu CM*, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, Chen YJ, Chen YJ, Lee EY and Lee WH, 2019, “High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells”, CELL METABOLISM, 29 (6):1334-1349. (SCIE) (IF: 20.565; SCIE ranking: 0.7%,3.2%)
  • Hu CM, Taso N, Wang TY, Chen YJ and Chang ZF, 2019, “Thymidylate Kinase is Critical for DNA Repair via ATM-dependent Tip60 Complex Formation”, FASEB J., 33(2):2017-2025. (SCIE) (IF: 5.595; SCIE ranking: 9.4%,22.1%,14.3%)
  • Chen YL, Hu CM, Hsu JT, Chang CC, Huang TY, Chiang PH, Chen WY, Chang YT, Chang MC, Tien YW, Lee EY, Jeng YM and Lee WH, 2018, “Cellular 5-hydroxylmethyl -cytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma”, Am J Cancer Res, 8(12):2548-2563. (SCIE) (IF: 3.998; SCIE ranking: 32.7%)
  • Huang SC, Wei PC, Hwang-Verslues WW, Kuo WH, Jeng YM, Hu CM, Shew JY, Huang CS, Chang KJ, Lee EY and Lee WH, 2017, “TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.”, EMBO Mol Med., 9(12):1660-1680. (SCIE) (IF: 10.293; SCIE ranking: 5.3%)
  • Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM and Lee WH., 2017, “Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate.”, Nat Commun., 8:14706. (SCIE) (IF: 12.353; SCIE ranking: 4.7%)
  • Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EH, Lee WH., 2015, “Novel small molecules disrupting Hec1/Nek2 interaction ablates tumor progression by triggering Nek2 degradation through a death-trap mechanism.”, ONCOGENE, 1220-1230. (SCIE) (IF: 6.854; SCIE ranking: 8.8%,11.3%,12.1%,16.8%)
  • Ngo B, Hu CM, Guo XE, Ngo B, Wei R, Zhu J and Lee WH., 2013, “Complementary interhelical interactions between three buried Glu-Lys pairs within three heptad repeats are essential for Hec1-Nuf2 heterodimerization and mitotic progression.”, JOURNAL OF BIOLOGICAL CHEMISTRY, 288(48), 34403-34413. (SCIE) (IF: 4.011; SCIE ranking: 25.6%)
  • Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, Qiu XL, Chen CF, Hu CM, Goldblatt E, Bhatia R, Chamberlin AR, Chen PL, Lee WH. , 2013, “A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.”, EMBO Molecular Medicine, 5(3), 353-365. (SCIE) (IF: 10.293; SCIE ranking: 5.3%)
  • Hu CM, Yeh MT, Tsao N, Chen CW, Gao QZ, Chang CY, Lee MH, Fang JM, Sheu SY, Lin CJ, Tseng MC, Chen YJ, Chang ZF, 2012, “Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair.”, CANCER CELL, 22(1), 36-50. (SCIE) (IF: 22.844; SCIE ranking: 2.6%,3.1%)
  • Hu CM, Chang ZF , 2010, “A bioluminescent method for measuring thymidylate kinase activity suitable for high-throughput screening of inhibitor.”, ANALYTICAL CHEMISTRY, 398(2), 269-271. (SCIE) (IF: 6.042; SCIE ranking: 4.9%)
  • Hu CM, Chang ZF., 2008, “Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status.”, CANCER RESEARCH, 68(8), 2831-2840. (SCIE) (IF: 9.13; SCIE ranking: 7.6%)
  • Hu CM, Chang ZF, 2007, “Mitotic control of dTTP pool: a necessity or coincidence? ”, JOURNAL OF BIOMEDICAL SCIENCE, 14(4), 491-497. (SCIE) (IF: 3.466; SCIE ranking: 34.6%,47.9%)
  • Ke PY, Hu CM, Chang YC, Chang ZF. , 2007, “Hiding human thymidine kinase 1 from APC/C- mediated destruction by thymidine binding.”, FASEB JOURNAL, 21(4), 1276-1284. (SCIE) (IF: 5.595; SCIE ranking: 9.4%,22.1%,14.3%)
  • Ke PY, Kuo YY, Hu CM, Chang ZF., 2005, “Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. ”, GENES & DEVELOPMENT, 19(16), 1920-1933. (SCIE) (IF: 9.462; SCIE ranking: 9.5%,4.8%,5.8%)